Literature DB >> 16794527

Accuracy of staging as a predictor for recurrence after liver transplantation for hepatocellular carcinoma.

Shimul A Shah1, Jensen C C Tan, Ian D McGilvray, Mark S Cattral, Sean P Cleary, Gary A Levy, Paul D Greig, David R Grant.   

Abstract

BACKGROUND: Tumor number, size, and macrovascular invasion (MacroVI) are the most widely used predictors of survival after liver transplantation (LT) for hepatocellular carcinoma (HCC). We analyzed all patients undergoing LT for HCC at our center to establish the accuracy of preoperative clinical staging and to determine which patients have a higher probability of being understaged.
METHODS: In all, 118 patients with confirmed HCC after LT from April 1991 to October 2004 at our institution were reviewed. All patients were monitored with serial imaging every 3 months to ensure their eligibility for LT within Milan criteria. Understaging in the 118 patients was defined as evidence on explant pathology that Milan criteria (TNM stage pT1 or pT2) had been exceeded.
RESULTS: Five-year DFS was 78% with a recurrence rate of 15% after a median follow-up after LT of 30 months. On explant pathology, 43% (51/118) of patients exceeded Milan criteria and had a worse DFS (1 year, 95% vs. 87%; 3 year, 87% vs. 64%; P=0.03) compared to those who met LT criteria. Understaging was more likely in patients with imaging characteristics of > or = 2 tumor nodules (P=0.005) and tumor growth > 0.25 cm/month (P=0.02) and pathologic findings of vascular invasion (P=0.001) and bilobar tumors (P=0.002).
CONCLUSIONS: Preoperative imaging every 3 months while on the waiting list frequently understages HCC as assessed by explant pathology. Recurrence after LT often occurred in patients that were understaged. Improving the accuracy of clinical staging and inclusion parameters will ensure proper organ allocation and acceptable outcomes after LT.

Entities:  

Mesh:

Year:  2006        PMID: 16794527     DOI: 10.1097/01.tp.0000226069.66819.7e

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  22 in total

1.  Liver transplantation for hepatocellular carcinoma on cirrhosis: strategies to avoid tumor recurrence.

Authors:  Marco Vivarelli; Andrea Risaliti
Journal:  World J Gastroenterol       Date:  2011-11-21       Impact factor: 5.742

2.  Risk Factors and Center-Level Variation in Hepatocellular Carcinoma Under-Staging for Liver Transplantation.

Authors:  Nadim Mahmud; Maarouf A Hoteit; David S Goldberg
Journal:  Liver Transpl       Date:  2020-08       Impact factor: 5.799

3.  Efficacy of contrast-enhanced FDG PET/CT in patients awaiting liver transplantation with rising alpha-fetoprotein after bridge therapy of hepatocellular carcinoma.

Authors:  Rania Refaat; Mohammad Abd Alkhalik Basha; Mohammed Sobhi Hassan; Rasha S Hussein; Ahmed A El Sammak; Dena Abd El Aziz El Sammak; Mohamed Hesham Saleh Radwan; Nahla M Awad; Somaia A Saad El-Din; Engi Elkholy; Dina R D Ibrahim; Shereen A Saleh; Iman F Montasser; Hany Said
Journal:  Eur Radiol       Date:  2018-06-12       Impact factor: 5.315

4.  MR visible localization device for radiographic-pathologic correlation of surgical specimens.

Authors:  Sonja Kinner; Tilman B Schubert; Elisabetta A Nocerino; Shannon Hynes; Timothy J Colgan; Agnes G Loeffler; Christopher Brace; Scott B Reeder; Emily Winslow
Journal:  Magn Reson Imaging       Date:  2016-11-27       Impact factor: 2.546

5.  Noninvasive radiomics signature based on quantitative analysis of computed tomography images as a surrogate for microvascular invasion in hepatocellular carcinoma: a pilot study.

Authors:  Shaimaa Bakr; Sebastian Echegaray; Rajesh Shah; Aya Kamaya; John Louie; Sandy Napel; Nishita Kothary; Olivier Gevaert
Journal:  J Med Imaging (Bellingham)       Date:  2017-08-21

6.  Utility of Tumor Burden Score to Stratify Prognosis of Patients with Hepatocellular Cancer: Results of 4759 Cases from ITA.LI.CA Study Group.

Authors:  Alessandro Vitale; Quirino Lai; Fabio Farinati; Laura Bucci; Edoardo G Giannini; Lucia Napoli; Francesca Ciccarese; Gian Lodovico Rapaccini; Maria Di Marco; Eugenio Caturelli; Marco Zoli; Franco Borzio; Rodolfo Sacco; Giuseppe Cabibbo; Roberto Virdone; Fabio Marra; Martina Felder; Filomena Morisco; Luisa Benvegnù; Antonio Gasbarrini; Gianluca Svegliati-Baroni; Francesco Giuseppe Foschi; Gabriele Missale; Alberto Masotto; Gerardo Nardone; Antonio Colecchia; Mauro Bernardi; Franco Trevisani; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2018-01-19       Impact factor: 3.452

Review 7.  Role of inflammatory markers as hepatocellular cancer selection tool in the setting of liver transplantation.

Authors:  Russell E Rosenblatt; Zaid H Tafesh; Karim J Halazun
Journal:  Transl Gastroenterol Hepatol       Date:  2017-11-21

8.  Loco-regional therapy in patients with Milan Criteria-compliant hepatocellular carcinoma and short waitlist time to transplant: an outcome analysis.

Authors:  Achuthan Sourianarayanane; Galal El-Gazzaz; Juan R Sanabria; K V Narayanan Menon; Cristiano Quintini; Koji Hashimoto; Dympna Kelly; Bijan Eghtesad; Charles Miller; John Fung; Federico Aucejo
Journal:  HPB (Oxford)       Date:  2012-03-27       Impact factor: 3.647

9.  Poorer survival in patients whose explanted hepatocellular carcinoma (HCC) exceeds Milan or UCSF Criteria. An analysis of liver transplantation in HCC in Australia and New Zealand.

Authors:  John W C Chen; Lilian Kow; Deborah J Verran; John L McCall; Stephen Munn; Glenda A Balderson; Jonathan W Fawcett; Paul J Gow; Robert M Jones; Gary P Jeffrey; Anthony K House; Simone I Strasser
Journal:  HPB (Oxford)       Date:  2009-02       Impact factor: 3.647

10.  Serological Risk Index Based on Alpha-Fetoprotein and C-Reactive Protein to Indicate Futile Liver Transplantation Among Patients with Advanced Hepatocellular Carcinoma.

Authors:  Arno Kornberg; Martina Schernhammer; Jennifer Kornberg; Helmut Friess; Katharina Thrum
Journal:  Dig Dis Sci       Date:  2018-09-27       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.